Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Gregory J. Riely; Douglas E. Wood; David S. Ettinger; Dara L. Aisner; Wallace Akerley; Jessica R. Bauman; Ankit Bharat; Debora S. Bruno; Joe Y. Chang; Lucian R. Chirieac; Malcolm DeCamp; Aakash P. Desai; Thomas J. Dilling; Jonathan Dowell; Gregory A. Durm; Scott Gettinger; Travis E. Grotz; Matthew A. Gubens; Aditya Juloori; Rudy P. Lackner; Michael Lanuti; Jules Lin; Billy W. Loo; Christine M. Lovly; Fabien Maldonado; Erminia Massarelli; Daniel Morgensztern; Trey C. Mullikin; Thomas Ng; Dawn Owen; Dwight H. Owen; Sandip P. Patel; Tejas Patil; Patricio M. Polanco; Jonathan Riess; Theresa A. Shapiro; Aditi P. Singh; James Stevenson; Alda Tam; Tawee Tanvetyanon; Jane Yanagawa; Stephen C. Yang; Edwin Yau; Kristina M. Gregory; Lisa Hang

doi:10.6004/jnccn.2204.0023

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Aakash P. Desai, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. LacknerMichael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Lisa Hang

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.

Original language	English
Pages (from-to)	249-274
Number of pages	26
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	22
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2204.0023
State	Published - May 2024

Keywords

Biomarkers, Tumor/genetics
Carcinoma, Non-Small-Cell Lung/therapy
Humans
Lung Neoplasms/diagnosis
Molecular Targeted Therapy/methods
Neoplasm Staging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2204.0023

Cite this

Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M., Desai, A. P., Dilling, T. J., Dowell, J., Durm, G. A., Gettinger, S., Grotz, T. E., Gubens, M. A., Juloori, A., ... Hang, L. (2024). Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22(4), 249-274. https://doi.org/10.6004/jnccn.2204.0023

@article{5fa7f416666845918bc35f7bdd700f3f,

title = "Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology",

abstract = "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.",

keywords = "Biomarkers, Tumor/genetics, Carcinoma, Non-Small-Cell Lung/therapy, Humans, Lung Neoplasms/diagnosis, Molecular Targeted Therapy/methods, Neoplasm Staging",

author = "Riely, {Gregory J.} and Wood, {Douglas E.} and Ettinger, {David S.} and Aisner, {Dara L.} and Wallace Akerley and Bauman, {Jessica R.} and Ankit Bharat and Bruno, {Debora S.} and Chang, {Joe Y.} and Chirieac, {Lucian R.} and Malcolm DeCamp and Desai, {Aakash P.} and Dilling, {Thomas J.} and Jonathan Dowell and Durm, {Gregory A.} and Scott Gettinger and Grotz, {Travis E.} and Gubens, {Matthew A.} and Aditya Juloori and Lackner, {Rudy P.} and Michael Lanuti and Jules Lin and Loo, {Billy W.} and Lovly, {Christine M.} and Fabien Maldonado and Erminia Massarelli and Daniel Morgensztern and Mullikin, {Trey C.} and Thomas Ng and Dawn Owen and Owen, {Dwight H.} and Patel, {Sandip P.} and Tejas Patil and Polanco, {Patricio M.} and Jonathan Riess and Shapiro, {Theresa A.} and Singh, {Aditi P.} and James Stevenson and Alda Tam and Tawee Tanvetyanon and Jane Yanagawa and Yang, {Stephen C.} and Edwin Yau and Gregory, {Kristina M.} and Lisa Hang",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2024",

month = may,

doi = "10.6004/jnccn.2204.0023",

language = "English",

volume = "22",

pages = "249--274",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "4",

}

Riely, GJ, Wood, DE, Ettinger, DS, Aisner, DL, Akerley, W, Bauman, JR, Bharat, A, Bruno, DS, Chang, JY, Chirieac, LR, DeCamp, M, Desai, AP, Dilling, TJ, Dowell, J, Durm, GA, Gettinger, S, Grotz, TE, Gubens, MA, Juloori, A, Lackner, RP, Lanuti, M, Lin, J, Loo, BW, Lovly, CM, Maldonado, F, Massarelli, E, Morgensztern, D, Mullikin, TC, Ng, T, Owen, D, Owen, DH, Patel, SP, Patil, T, Polanco, PM, Riess, J, Shapiro, TA, Singh, AP, Stevenson, J, Tam, A, Tanvetyanon, T, Yanagawa, J, Yang, SC, Yau, E, Gregory, KM & Hang, L 2024, 'Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 22, no. 4, pp. 249-274. https://doi.org/10.6004/jnccn.2204.0023

TY - JOUR

T1 - Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

AU - Riely, Gregory J.

AU - Wood, Douglas E.

AU - Ettinger, David S.

AU - Aisner, Dara L.

AU - Akerley, Wallace

AU - Bauman, Jessica R.

AU - Bharat, Ankit

AU - Bruno, Debora S.

AU - Chang, Joe Y.

AU - Chirieac, Lucian R.

AU - DeCamp, Malcolm

AU - Desai, Aakash P.

AU - Dilling, Thomas J.

AU - Dowell, Jonathan

AU - Durm, Gregory A.

AU - Gettinger, Scott

AU - Grotz, Travis E.

AU - Gubens, Matthew A.

AU - Juloori, Aditya

AU - Lackner, Rudy P.

AU - Lanuti, Michael

AU - Lin, Jules

AU - Loo, Billy W.

AU - Lovly, Christine M.

AU - Maldonado, Fabien

AU - Massarelli, Erminia

AU - Morgensztern, Daniel

AU - Mullikin, Trey C.

AU - Ng, Thomas

AU - Owen, Dawn

AU - Owen, Dwight H.

AU - Patel, Sandip P.

AU - Patil, Tejas

AU - Polanco, Patricio M.

AU - Riess, Jonathan

AU - Shapiro, Theresa A.

AU - Singh, Aditi P.

AU - Stevenson, James

AU - Tam, Alda

AU - Tanvetyanon, Tawee

AU - Yanagawa, Jane

AU - Yang, Stephen C.

AU - Yau, Edwin

AU - Gregory, Kristina M.

AU - Hang, Lisa

PY - 2024/5

Y1 - 2024/5

N2 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.

AB - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.

KW - Biomarkers, Tumor/genetics

KW - Carcinoma, Non-Small-Cell Lung/therapy

KW - Humans

KW - Lung Neoplasms/diagnosis

KW - Molecular Targeted Therapy/methods

KW - Neoplasm Staging

UR - http://www.scopus.com/inward/record.url?scp=85193475487&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2204.0023

DO - 10.6004/jnccn.2204.0023

M3 - Article

C2 - 38754467

AN - SCOPUS:85193475487

SN - 1540-1405

VL - 22

SP - 249

EP - 274

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 4

ER -

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this